The partnership expands Owlet’s pediatric DME distribution footprint and supports extended commercial activation
LEHI, Utah–(BUSINESS WIRE)–$owlt #babymonitor—Owlet, Inc. (“Owlet” or the “Company”) (NYSE: OWLT), the pioneer of smart infant monitoring, today announced a new strategic partnership with PromptCare, a leading national respiratory services and durable medical equipment (DME) provider specializing in adult and pediatric care. The partnership expands Owlet’s clinical and DME footprint across key U.S. regions and supports broader access to the Company’s FDA-cleared, prescription pulse oximeter, BabySat, through established pediatric care pathways.
“This partnership represents a meaningful step forward in Owlet’s DME expansion strategy,” said Jonathan Harris, President and CEO of Owlet. “PromptCare’s deep experience in pediatric respiratory care and strong relationships with children’s hospitals make them an ideal partner as we continue to scale our clinical distribution model and make an impact where it matters most.”
PromptCare brings more than 40 years of experience in respiratory care delivery, operating from 25+ locations across the United States with a large, clinically trained workforce supporting pediatric and home-based care. The partnership aligns Owlet with a DME organization that already supports pediatric and respiratory care programs in children’s hospitals and healthcare systems, several of which have expressed interest in Owlet partnering with PromptCare to support their initiatives.
“Owlet’s technology complements our pediatric respiratory offerings and supports our mission to deliver high-quality, clinically relevant care in the home,” said Matt Keppler, President of Respiratory at PromptCare. “We’re excited to pilot this partnership and bring additional monitoring options to the families and providers we serve.”
The collaboration strengthens Owlet’s position within the pediatric DME channel, enhances brand legitimacy within established hospital-to-home care pathways, and expands referral opportunities for both organizations. The partnership is expected to contribute to incremental unit shipments through PromptCare as pilot programs expand.
To learn more about Owlet and its line of pediatric health monitoring devices, including BabySat and FDA-cleared Dream Sock®, please visit www.owletcare.com.
About Owlet, Inc.
Owlet, Inc. (NYSE: OWLT), a leading pediatric health platform, is the only company in the world to offer U.S. FDA-cleared and internationally medically-certified wearable pediatric monitors, delivering hospital-grade technology directly in the home. Our award-winning pediatric products and innovative software combine clinically tested monitoring systems, an integrated video platform, and a simple, easy-to-use app, providing parents with real-time health insights to stay informed on their child’s well-being, support restful sleep, and provide peace of mind anywhere. Since 2012, more than 2.5 million parents have trusted Owlet to monitor their children’s well-being and sleep. This adoption has fueled one of the largest collections of pediatric health and sleep data in the world, powering innovations that bridge the critical gap between hospital and home. Owlet is driving a new standard in pediatric wellness by pairing advanced medical technology with consumer-friendly design. Our mission is simple yet ambitious: to give every baby and every family the best possible start in life. Learn more at www.owletcare.com and follow us on LinkedIn and Instagram for company news and updates.
About PromptCare
PromptCare is a leading national provider of in-home and alternate-site infusion therapies and high-tech, hands-on respiratory services. With 40 years of providing compassionate clinical care to patients with chronic and rare health conditions, PromptCare holds accreditations from URAC and ACHC. The company’s pharmacists, respiratory therapists, nurses, and dietitians treat patients across the United States. For more information, please visit promptcare.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (the “Reform Act”). All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements regarding the Company’s expectations regarding the outcomes and benefits of Owlet’s partnership with PromptCare and other third-party DME partners (including the scope, timing, and success of pilot programs and commercial activation); the Company’s ability to expand insurance-supported distribution channels, including through third-party DME partners; the availability, scope and continuity of reimbursement coverage under commercial plans, Medicaid, TRICARE and other government or private payor programs; and potential market reception and competitive positioning. In some cases, you can identify forward-looking statements by terms such as “estimate,” “may,” “believes,” “plans,” “expects,” “anticipates,” “intends,” “goal,” “potential,” “upcoming,” “outlook,” “guidance,” the negation thereof, or similar expressions, although not all forward-looking statements contain these identifying words. Forward-looking statements are based on the Company’s expectations at the time such statements are made, speak only as of the dates they are made, and are susceptible to a number of risks, uncertainties, and other factors. For all such forward-looking statements, the Company claims the protection of the safe harbor for forward-looking statements contained in the Reform Act. The Company’s actual results, performance or achievements may differ materially from any future results, performance or achievements expressed or implied by its forward-looking statements. Many important factors could affect the Company’s future results and cause those results to differ materially from those expressed in or implied by the Company’s forward-looking statements. Such factors include, but are not limited to, (i) the commercial success of BabySat, related software and services, and the Company’s ability to execute and scale DME chanel initiatives, including the PromptCare partnership and any related operational, clinical workflow, or systems integrations; (ii) variability in insurance coverage, reimbursement rates, documentation requirements, clinical eligibility criteria, and payor determinations, including the risk that coverage may be reduced, delayed, denied or discontinued; (iii) the regulatory pathway for Owlet’s products, including submissions to, actions taken by and decisions and responses from regulators, such as the FDA and similar regulators outside of the United States, as well as Owlet’s ability to obtain and maintain regulatory approval or certification for its products and other regulatory requirements and legal proceedings; (iv) the Company’s and its partners’ obligations relating to data privacy, security and the exchange and use of health information (including HIPAA, HITECH and comparable laws, and evolving requirements governing such activities), and risks of cybersecurity incidents or changes in applicable standards or interpretations; (v) the performance of, and Owlet’s ability to maintain and expand, its relationship with PromptCare and other third-party DME and distribution partners and other third-party technology, cloud, manufacturing and distribution partners; (vi) Owlet’s competition and the Company’s ability to profitably grow and manage growth; (vii) the ability of Owlet to implement strategic initiatives, reduce costs, grow revenues, develop and launch new products, successfully execute and support integrations with third-party systems, innovate and enhance existing products, meet customer demands and adapt to changes in consumer and provider preferences and retail and healthcare trends; (viii) Owlet’s ability to acquire, defend and protect its intellectual property and satisfy regulatory requirements concerning privacy and data protection; (ix) Owlet’s ability to maintain relationships with healthcare providers and health systems, channel partners, customers, manufacturers and suppliers; (x) impacts from compliance with applicable laws or regulations; (xi) the impact of and disruption to Owlet’s business, financial condition, operations, supply chain and logistics due to economic and other conditions beyond the Company’s control; (xii) adverse impacts from other economic, business, regulatory, competitive or other factors, such as changes in discretionary consumer spending and consumer preferences, evolution of reimbursement and remote patient monitoring programs; and (xiii) Owlet’s reliance on a limited number of third-party DME, fulfillment and distribution partners for prescription-based revenue channels, and the risk that changes in those relationships, including the risk that pilot programs may not convert into broader rollouts or may be delayed due to operational, clinical, reimbursement, contracting, or payor-related factors, could adversely affect access, reimbursement or revenue growth; (xiv) other risks and uncertainties set forth in the Company’s other releases, public statements and filings with the U.S. Securities and Exchange Commission (“SEC”), including those identified in the “Risk Factors” section of the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, and as any such factors may be updated from time to time in the Company’s other filings with the SEC. All such forward-looking statements attributable to the Company or any person acting on the Company’s behalf are expressly qualified in their entirety by the cautionary statements contained or referred to above. Moreover, the Company operates in an evolving environment. New risk factors and uncertainties may emerge from time to time, and factors that the Company currently deems immaterial may become material, and it is impossible for the Company to predict such events or how they may affect Owlet. Except as required by law, the Company assumes no obligation to update any forward-looking statements after the date of this press release, whether because of new information, future events or otherwise, although Owlet may elect to do so from time to time. The Company does not endorse any projections regarding future performance that may be made by third parties.
Contacts
Owlet Media Contact:
[email protected]
Owlet Investor Contact:
[email protected]
Owlet Health Contact:
[email protected]
PromptCare Contact:
[email protected]
